A Phase 3, Randomized, Blinded, Active-controlled Study to Evaluate the Immunogenicity and Safety of Walvax’s 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13-TT) as Compared to Pfizer’s 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Co-administered with EPI Vaccines at 2, 4, and 12–15 months of age, to Healthy Infants in Indonesia
Outcome
To demonstrate the non-inferiority of the serostatus-specific immune responses elicited by PCV13-TT, for the 13 vaccine-serostatuss (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F), as compared to the serostatus-specific immune responses elicited by PCV13
Sponsor
Yuxi Walvax Biotechnology Co., Ltd
Date
- Present
Subjects
300 subjects